Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS.

Shefner JM, Wolff AA, Meng L.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):582-5. doi: 10.3109/21678421.2013.817587. Epub 2013 Aug 19.

PMID:
23952600
2.

A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis.

Shefner JM, Watson ML, Meng L, Wolff AA; Neals/Cytokinetics STUDY Team.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):574-81. doi: 10.3109/21678421.2013.822517. Epub 2013 Aug 19.

PMID:
23952636
3.

A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.

Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, Andrews JA; ; ON BEHALF OF THE BENEFIT-ALS STUDY GROUP.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):426-35. doi: 10.3109/21678421.2016.1148169. Epub 2016 Mar 16.

PMID:
26982815
4.

Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model.

Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, Morgans DJ, Malik FI, Jasper JR.

PLoS One. 2014 May 7;9(5):e96921. doi: 10.1371/journal.pone.0096921. eCollection 2014.

5.

Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model.

Miciak JJ, Warsing LC, Tibbs ME, Jasper JR, Jampel SB, Malik FI, Tankersley C, Wagner KR.

Muscle Nerve. 2013 Aug;48(2):279-85. doi: 10.1002/mus.23848. Epub 2013 Jun 29.

PMID:
23512724
6.

A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis.

Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI; Tirasemtiv in Myasthenia Gravis Study Group.

Neurotherapeutics. 2015 Apr;12(2):455-60. doi: 10.1007/s13311-015-0345-y.

7.

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, Clawson L, Haas L, Rothstein JD.

Amyotroph Lateral Scler. 2010 May 3;11(3):266-71. doi: 10.3109/17482960903307805.

PMID:
19961264
8.

Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.

Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA; Neals/Cytokinetics Study Team.

Amyotroph Lateral Scler. 2012 Sep;13(5):430-8. doi: 10.3109/17482968.2012.684214. Epub 2012 May 16.

PMID:
22591195
9.

VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.

Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb 6:1-8. doi: 10.1080/21678421.2018.1426770. [Epub ahead of print]

PMID:
29402141
10.

Tirasemtiv amplifies skeletal muscle response to nerve activation in humans.

Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S, Enoka RM, Morgans DJ, Wolff AA, Malik FI.

Muscle Nerve. 2014 Dec;50(6):925-31. doi: 10.1002/mus.24239.

11.

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, Phillips LH, Chapin J, Gelinas DF, Lou JS.

Amyotroph Lateral Scler. 2008 Oct;9(5):266-72. doi: 10.1080/17482960802028890.

13.

Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study.

Nefussy B, Artamonov I, Deutsch V, Naparstek E, Nagler A, Drory VE.

Amyotroph Lateral Scler. 2010;11(1-2):187-93. doi: 10.3109/17482960902933809.

PMID:
19449238
14.

Creatine for amyotrophic lateral sclerosis/motor neuron disease.

Pastula DM, Moore DH, Bedlack RS.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005225. doi: 10.1002/14651858.CD005225.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD005225.

PMID:
20556761
15.

Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.

Gordon PH, Cheng B, Katz IB, Mitsumoto H, Rowland LP.

Neurology. 2009 Jun 2;72(22):1948-52. doi: 10.1212/WNL.0b013e3181a8269b.

PMID:
19487653
16.
17.

Creatine for amyotrophic lateral sclerosis/motor neuron disease.

Pastula DM, Moore DH, Bedlack RS.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD005225. doi: 10.1002/14651858.CD005225.pub3. Review.

PMID:
23235621
18.

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.

Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J; Northeast ALS Consortium.

Neurology. 2003 Aug 26;61(4):456-64.

PMID:
12939417
19.

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease.

Dalbello-Haas V, Florence JM, Krivickas LS.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005229. doi: 10.1002/14651858.CD005229.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;5:CD005229.

PMID:
18425913
20.

Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease.

Bauer TA, Wolff AA, Hirsch AT, Meng LL, Rogers K, Malik FI, Hiatt WR.

Vasc Med. 2014 Aug;19(4):297-306. Epub 2014 May 28.

PMID:
24872402

Supplemental Content

Support Center